Tag: US
Poly Medicure acquires PendraCare Group, Netherlands for Rs 188.5 crores
This “bolt-on” acquisition provides Polymed with an opportunity to scale its cardiology business globally with immediate access to world’s most regulated markets of Europe and the US
Sun Pharma’s phase 3 trials of ILUMYA support potential U.S. submission...
Both pivotal studies met their primary endpoint with statistically significant improvements based on ACR20 response rates at Week 24 with tildrakizumab 100 mg (ILUMYA) compared to placebo
UK biopharma venture financing QoQ doubles to $1.1 billion in Q1...
This surge highlights investor appetite for breakthrough innovation, but growing dependence on US capital and policy-driven cost pressures signal an urgent need to strengthen domestic investment
Shrimp export volume growth to be flattish this fiscal due to...
India exports close to 48% of its produce to the US
GBA Group’s Eureka acquires majority stake in Teena Biolabs
Through the merger with Teena, Eureka will become a leading service provider for pharmaceutical analysis in India with a total of two US-FDA approved sites
HRV Global Life Sciences strengthens global presence at DCAT Week 2025...
The company has a pipeline of over 25 products to be launched in US and European markets in the current year
World Tuberculosis Day 2025: Funding cuts threaten global TB control efforts,...
The recent funding cuts to TB programs, particularly from the US, that raise serious concerns about the future of TB control and treatment efforts
Shilpa Medicare launches ‘hybrid CDMO’ at DCAT
Integrated CDMO has capabilities spanning small and large molecules as well as peptides with ‘off-the-shelf’ commercially ready formulations for license
Zydus & Beihai Biotech sign an exclusive deal to commercialize BEIZRAY...
Beihai Biotech shall receive upfront payments, sales targets-based milestone payments and a share of BEIZRAY’s net profits earned in the US as per the terms of the agreement
Zydus partners Synthon to develop & commercialize novel oncology product in...
This 505(B)(2) Oncology product will likely be filed in 2026 and will be offering additional strengths that is intended to provide reduced pill burden, flexibility for dose adjustment